Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05172596 · ClinicalTrials.gov registry record · Phase 2
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT05172596 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 146 participants.
The verdict
NCT05172596, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma
Interventions
- BIOLOGICAL PHE885
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2025-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05172596
The ClinicalTrials.gov registry entry for NCT05172596 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PHE885 is the first listed.
NCT05172596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05172596 about?
NCT05172596 is a clinical study titled "PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma". This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma
What is the current status of trial NCT05172596?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2022-03-03. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT05172596?
The interventions under investigation include: PHE885 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05172596?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.